Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

Lundbeck signs up for Sanifit’s series D round
Cardiovascular drug developer Sanifit raised $82.1m including $62.8m from investors that included existing backer Lundbeckfonden Ventures to bring its overall financing to $149m.
CureFit stretches to $120m in Unilever-backed round
CureFit had held discussions with SoftBank Vision Fund over a $200m investment, but Unilever Ventures has instead stepped up as part of a $120m round.
Nice takes a step to series D stage
Limited edition sneakers trading platform Nice has secured tens of millions of dollars in a series D round led by the SoftBank-backed TPG-SV China Ventures fund.
Acutus Medical pumps in $100m
The cardiac imaging system developer secured $100m in a GE Ventures-backed series D round in addition to $70m in debt financing.
Haoqipei motors on with $60m series D
Existing shareholder Access Industries has led a $60m series D round for business-to-business car parts marketplace Haoqipei, while Susquehanna International Group also returned.
Optimizely orchestrates $50m series D round
The website optimisation tools provider increased its overall funding to $200m with an Accenture-backed series D round secured alongside a $55m credit facility from Bridge Bank.
Zhenkunhang procures $160m in series D funding
Tencent has led a $160m series D round for business-to-business e-commerce platform Zhenkunhang that was also backed by return investor Legend Capital.
Quartet uncorks $60m series D
GV and new strategic partner Centene both participated in a round that boosted the collaborative mental healthcare platform’s total funding to $153m.
SecurityScorecard marks off $50m series D
The cybersecurity risk-scoring platform developer has increased its total funding to $110m with the series D round, which featured Intel Capital and Axa Ventures.
InGeneron extends series D to $43m
Sanford Health has provided $23m in funding to increase the regenerative cell therapy provider's series D round to $43m, having initially supplied the first $20m in 2017.

test reg